PRELIMINARY RESULTS OF A PHASE 2 TRIAL OF OBINUTUZUMAB, IN COMBINATION WITH IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE (O-ICE) IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH RELAPSED/ REFRACTORY MATURE B-CELL NON-HODGKIN LYMPHOMA. (October 2022)